Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Cancer Therapeutics

Background:

• NAD(P)H:quinone oxidoreductase 1 (NQO1) selectively activates antitumor agents via two-electron reduction.
• Cytochrome P450 reductase (CPR) can mediate one-electron reduction, leading to potential hepatotoxicity.
• Developing NQO1-specific compounds is crucial for targeted cancer therapy with improved safety.

Purpose of the Study:

• To discover novel quinone-directed compounds with high selectivity for NQO1 over CPR.
• To identify potential anticancer agents with reduced risk of CPR-mediated toxicity.
• To explore structure-activity relationships for optimizing NQO1 substrate specificity.

Main Methods:

• Structure-activity relationship (SAR) studies to design and synthesize novel quinone derivatives.
• Biochemical assays to evaluate NQO1 and CPR selectivity.
• Electrochemical studies to understand redox mechanisms.
• Molecular docking to analyze binding interactions.
• In vitro and in vivo cancer models to assess efficacy.

Main Results:

• Several novel quinone-based antitumor agents were identified as specific NQO1 substrates.
• Compound 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-dione (12b) exhibited superior selectivity for NQO1 (selectivity ratio = 6.37) compared to β-lapachone (1.36).
• Compound 12b demonstrated efficient cancer cell killing in vitro and in vivo models, with electrochemical and docking studies explaining its selectivity.
• 12b showed minimal reduction by CPR, indicating a potentially favorable safety profile.

Conclusions:

• Compound 12b is a highly selective NQO1 substrate with significant potential as a safe and effective anticancer agent.
• The identified scaffold offers a promising starting point for developing next-generation NQO1-targeted cancer therapies.
• This study highlights the importance of NQO1 selectivity in designing safer chemotherapeutics.